Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK
Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, announced that Cancer Research UK, the world’s leading cancer charity dedicated to saving lives, has formally approved Teon’s TT-702 program to enter into a clinical collaboration. TT-702, a first-in-class A2BR-specific antagonist being pursued in prostate cancer and other tumor types, expects to initiate a Phase 1b/2a clinical study in early 2021. In a collaboration, Cancer Research UK would sponsor and oversee the clinical trial, which will be run through the Centre for Drug Development. Future considerations would be contingent upon achievement of TT-702 development milestones by Teon.
“We are excited for the opportunity to collaborate with Cancer Research UK,” said Ken Horne, President and Chief Operating Officer of Teon Therapeutics. “They have helped develop 10 marketed cancer drugs, including Zytiga (abiraterone), Lynparza (olaparib), and Balversa (erdafitinib), so it is a tremendous honor to be approved to partner with Cancer Research UK under its Clinical Development Partnership initiative, which has seen 27 early clinical development collaborations established to date. We look forward to announcing more details around our collaboration in early 2021.”